PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31059692-6	2019	The effect of selective pharmacological PLD1 (VU0359595) and PLD2 (VU0285655-1) inhibitors demonstrated that ERK1/2 and NFkappaB activation were downstream events of both PLD isoforms.	VU0359595	46-55	phospholipase D1	Homo sapiens	40-44
33191863-5	2020	MATERIAL AND METHODS: Cell lines U266 and H929 were treated with PLD1 specific inhibitor VU0359595 combined bortezomib, a proteasome inhibitor.	VU0359595	89-98	phospholipase D1	Homo sapiens	65-69
33191863-10	2020	VU0359595 also strengthened bortezomib-induced apoptosis via activating caspase-8, caspase-9, caspase-3; and down-regulating the expressions of anti-apoptosis proteins BCL-2.	VU0359595	0-9	caspase 8	Homo sapiens	72-81
33191863-10	2020	VU0359595 also strengthened bortezomib-induced apoptosis via activating caspase-8, caspase-9, caspase-3; and down-regulating the expressions of anti-apoptosis proteins BCL-2.	VU0359595	0-9	caspase 9	Homo sapiens	83-92
33191863-10	2020	VU0359595 also strengthened bortezomib-induced apoptosis via activating caspase-8, caspase-9, caspase-3; and down-regulating the expressions of anti-apoptosis proteins BCL-2.	VU0359595	0-9	caspase 3	Homo sapiens	94-103
33191863-10	2020	VU0359595 also strengthened bortezomib-induced apoptosis via activating caspase-8, caspase-9, caspase-3; and down-regulating the expressions of anti-apoptosis proteins BCL-2.	VU0359595	0-9	BCL2 apoptosis regulator	Homo sapiens	168-173
33191863-11	2020	In addition, the bortezomib-induced cytotoxicity on MM cells was significantly augmented by VU0359595 through efficient suppression of the mTOR/NF-kappaB signal pathway.	VU0359595	92-101	mechanistic target of rapamycin kinase	Homo sapiens	139-143
33191863-11	2020	In addition, the bortezomib-induced cytotoxicity on MM cells was significantly augmented by VU0359595 through efficient suppression of the mTOR/NF-kappaB signal pathway.	VU0359595	92-101	nuclear factor kappa B subunit 1	Homo sapiens	144-153
31059692-6	2019	The effect of selective pharmacological PLD1 (VU0359595) and PLD2 (VU0285655-1) inhibitors demonstrated that ERK1/2 and NFkappaB activation were downstream events of both PLD isoforms.	VU0359595	46-55	mitogen-activated protein kinase 3	Homo sapiens	109-115
31059692-6	2019	The effect of selective pharmacological PLD1 (VU0359595) and PLD2 (VU0285655-1) inhibitors demonstrated that ERK1/2 and NFkappaB activation were downstream events of both PLD isoforms.	VU0359595	46-55	nuclear factor kappa B subunit 1	Homo sapiens	120-128
25967349-7	2015	At 500nM, the PLD1 inhibitor VU0359595 reduced proliferation in PLD2-deficient cells, but also in PLD1-deficient cells stimulated by IGF-1 or phorbol ester.	VU0359595	29-38	phospholipase D1	Mus musculus	14-18
25967349-7	2015	At 500nM, the PLD1 inhibitor VU0359595 reduced proliferation in PLD2-deficient cells, but also in PLD1-deficient cells stimulated by IGF-1 or phorbol ester.	VU0359595	29-38	phospholipase D2	Mus musculus	64-68
25967349-7	2015	At 500nM, the PLD1 inhibitor VU0359595 reduced proliferation in PLD2-deficient cells, but also in PLD1-deficient cells stimulated by IGF-1 or phorbol ester.	VU0359595	29-38	phospholipase D1	Mus musculus	98-102
25967349-7	2015	At 500nM, the PLD1 inhibitor VU0359595 reduced proliferation in PLD2-deficient cells, but also in PLD1-deficient cells stimulated by IGF-1 or phorbol ester.	VU0359595	29-38	insulin-like growth factor 1	Mus musculus	133-138
24262632-4	2014	Downregulation of PLD1 and exposure to the PLD1 inhibitor VU0359595 attenuated PLD activity and strongly reduced the mitogenic activity of serum and IGF-1.	VU0359595	58-67	phospholipase D1	Rattus norvegicus	43-47
24262632-4	2014	Downregulation of PLD1 and exposure to the PLD1 inhibitor VU0359595 attenuated PLD activity and strongly reduced the mitogenic activity of serum and IGF-1.	VU0359595	58-67	insulin-like growth factor 1	Rattus norvegicus	149-154